[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][C][C@H1][Branch1][C][C][O][C][=Branch1][C][=O][C@H1][Branch1][C][C][N][P@][=Branch1][C][=O][Branch2][Ring1][Branch2][O][C][C@H1][O][C][C@H1][Branch1][Ring2][O][Ring1][Branch1][N][C][=C][C][=Branch1][=Branch1][=N][C][Ring1][=Branch1][=O][N][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Br]"}, {"from": "gpt", "value": "The molecule is a liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation."}]